Hyperprolactinemia has been reported in 30 to 70% of patients with chronic renal failure, with more frequent elevations and higher levels being reported in women. Only a fraction of all cases, less than 5% in our series, may be attributed to drugs. What then, is the cause and significance of this yet another endocrine abnormality in uremia?
Impaired degradation of the hormone accounts at least in part for this abnormality, because the metabolic clearance of human 1311-prolactin is reduced by 33% as compared with normal controls. Increased secretion and resistance to dopaminergic suppression are much more important (1, 2) . The possibility that hyperprolactinemia is caused by the accumulation of a large prohormone or degraded hormone fragments has been ruled out by chromatographic studies. Sephadex G-75 gel filtration has shown that nearly all the endogenous plasma prolactin immunoreactivity in patients with renal failure is eluted as· prolactin monomer. Furthermore, 30 minutes following a single intravenous injection of 1311-human prolactin, 94% of the immunoprecipitable radioactivity is also eluted in the position of the prolactin monomer (1) .
Unlike other pituitary peptide hormones, the secretion of prolactin is under tonic inhibition of a hypothalamic dopaminergic mechanism (3). Other neurotransmitters, notably norepinephrine and serotonin, exert a modulating effect (4) . Based on the studies showing that proestrus prolactin surge in the rat could be suppressed by either prazosin or clonidine, it has been suggested that norepinephrine may have a stimulatory role on prolactin secretion, since both pharmacologic agents will block noradrenergic function. Serotonin neuron is believed to stimulate the secretion of a prolactin-releasing factor. The observation that the prolactin secretion rate is at least three times higher in uremic patients suggests there may be a loss of the feedback inhibition of prolactin secretion, perhaps related to altered catecholamine metabolism in the hypothalamus (1) .
The phenomenon of dopamine resistance is interesting and suggests an independent pituitary defect. During dopamine infusion plasma prolactin levels fell by less than 10% in uremic patients, compared to 40% in normal controls and renal transplant recipients, a highly signific- (2). This unique feature of prolactin unsuppressibility is also observed in response to a single dose of 2.5 mg of bromocriptine (5), but can be overcome by long-term treatment with 5 mg per day of bromocriptine, which invariably restores plasma prolactin levels to normal (6) . Lactotroph unresponsiveness in uremia is also demonstrated after administration of thyrotropin-releasing hormone (TRH) during which the rise in plasma prolactin is markedly blunted (2) . The nature of this lactotroph resistance remains speculative. There may bequantitative or qualitative alterations in the dopamine receptors or factors in uremia may interfere with the binding of dopamine to its receptors. Alternatively, there may be some disturbances in post-receptor metabolism.
With the exception of galactorrhea, the biologic significance of hyperprolactinemia in renal patients is by and large unclear. In the absence of kidney function the potential antidiuretic effect of prolactin is clearly meaningless. That prolactin might regulate fluid and electrolyte movements at sites other than kidney remains to be shown (7) .
Prolactin, however, is intimately linked to the function of the gonads through its effects on the hypothalamicpituitary axis (8, 9) . Excessive prolactin inhibits the secretion of luteinizing hormone-releasing hormone by the hypothalamus and of gonadotropins by the pituitary. The ability of prolactin to suppress the postcastration rise of luteinizing hormone and follicle-stimulating hormone is evidence of its role in reproductive biology. In men hyperprolactinemia is usually associated with a decline in libido and potency independent of any testosterone deficiency. In rats, hyperprolactinemia suppresses copulatory behavior without altering plasma testosterone levels. It has been suggested that prolactin may affect sexual behavior through its direct action on the brain, because it was reported to regulate dopamine turnover in the hypothalamus.
In uremic women, the consequences of impaired gonadotropin secretion (acyclicity and lack of response to the positive feedback effect of estrogen) may be attributable to hyperprolactinemia, as may be the failure of follicle-stimulating and luteinizing hormones to rise adequately in men (6, 10) . Effective suppression of pro-lactin, nevertheless, does not always restore gonadal function (5, 6) . Factors other than hyperprolactinemia, such as primary end organ damage, abnormal brain cathecholamine metabolism, psychological stress, and other unidentified causes may also be important in causing gonadal dysfunction in uremia.
